Sponsor or institution

Clinical trials and research at National Institute of Allergy and Infectious Diseases (NIAID)

• 50Clinical trials
• 22Countries

Newest trials

All recruiting trials (50)

• Expanding HIV-positive donor livers for HIV-positive recipients

  This study tests whether liver transplants from HIV-positive donors to HIV-positive recipients are safe regarding opportunistic infections and cancer.

  Recruiting at 2 sites National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 1 other locations · NCT07778459

• HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters

  This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.

  Recruiting at 2 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 7 other locations · NCT07757802

• Orally ingested yeast designed to express a tetra-specific anti-toxin for Clostridioides difficile safety study

  This first-in-human trial tests a yeast-based medicine (FZ002) to see if it is safe and tolerable for adults with no active infection, using a placebo for comparison.

  Recruiting Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Knoxville, Tennessee · NCT07649096

• Using alpha-gal KO pork to see if it reduces reactions in people with Alpha-gal Syndrome

  This study tests whether eating pork that lacks the alpha-gal allergen lowers reaction risk for people with Alpha-gal Syndrome, using a crossover design where each participant tries both KO and wild-type pork on separate days.

  Recruiting Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Little Rock, Arkansas and 3 other locations · NCT07611435

• DV700P-RNA and DV701B1.1-RNA HIV vaccines with ART interruption in adults with HIV

  This early-phase study tests two experimental HIV vaccines in adults living with HIV to see if they are safe and can help build antibody responses, with a closely monitored ART pause to observe immune effects.

  Recruiting at 4 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 15 other locations · NCT07569029

• Reducing Immunosuppression by 50% in Young Liver Transplant Recipients

  This study tests whether cutting the immunosuppressive medicine by half in children with liver transplants is safe and effective.

  Recruiting at 7 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 10 other locations · NCT07549503

• Lymph node examination during cat allergy immunotherapy

  This project will test how lymph nodes react after a small cat allergen skin challenge in people with cat allergy who are either on long-term allergy shots or have never had immunotherapy.

  Recruiting Early Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Boston, Massachusetts · NCT07447869

• Safety and drug levels of three lab-made HIV antibodies in adults without HIV

  This study will test whether one or combinations of three lab-made HIV antibodies given by IV or under the skin are safe and how long they stay in the body in healthy adults without HIV.

  Recruiting at 5 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 10 other locations · NCT07390955

• Testing two V2-apex HIV vaccine candidates (DV201P-RNA and DV202B1-RNA) in adults without HIV

  This Phase 1 test will try two mRNA HIV vaccine candidates designed to trigger V2-apex broadly neutralizing antibody responses in healthy adults without HIV.

  Recruiting at 7 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Atlanta, Georgia and 6 other locations · NCT07390474

• Dasatinib to Try Lower Hidden HIV in People on ART

  We’re testing if the drug dasatinib can help reduce the hidden HIV reservoir in people on effective ART.

  Recruiting at 3 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Chicago, Illinois and 2 other locations · NCT07342491

• Biomarkers that predict peanut allergy reactions during a feeding test

  This study tests whether biomarkers can predict which children and teens will react during a peanut oral food challenge.

  Recruiting at 8 sites National Institute of Allergy and Infectious Diseases (NIAID) · Little Rock, Arkansas and 9 other locations · NCT07279467

• Alendronate to see if it reduces HIV reservoir in people on ART

  This study tests whether alendronate can help shrink the HIV reservoir in people living with HIV who are on antiretroviral therapy.

  Recruiting at 4 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 4 other locations · NCT07216794

• First use of VNT-101 in people to test safety and how the body handles it

  This Phase 1 trial will test whether single and multiple oral doses of the experimental antiviral VNT-101 are safe and tolerable in healthy adults aged 18–59.

  Recruiting Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Overland Park, Kansas · NCT07169318

• Daily rifapentine and isoniazid for TB prevention in children under 13, with and without HIV

  This study tests a 28-day daily course of rifapentine plus isoniazid to prevent tuberculosis in children under 13, including kids with HIV who are on antiretroviral therapy.

  Recruiting at 5 sites Phase 1/2 National Institute of Allergy and Infectious Diseases (NIAID) · Gaborone and 10 other locations · NCT07124559

• Blinded pH1N1 (H1N1) viral challenge in healthy adults

  This will try different doses of the pH1N1 (H1N1) influenza virus or a sham inoculation in healthy adults to find the dose that reliably produces mild infection for use in future flu tests.

  Recruiting at 2 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 1 other locations · NCT07110532

• Stopping versus reducing tocilizumab for people with well-controlled giant cell arteritis

  This trial will test whether stopping tocilizumab or reducing its dose better maintains remission in people with giant cell arteritis who have been on high-dose tocilizumab for at least 12 months and off steroids for at least three months.

  Recruiting at 7 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Atlanta, Georgia and 6 other locations · NCT07108387

• Ublituximab for early, autoantibody‑positive immune‑mediated necrotizing myopathy

  This trial will test whether adding ublituximab to standard immunosuppressive therapy helps adults with early, active anti‑SRP or anti‑HMGCR antibody–positive immune‑mediated necrotizing myopathy improve over 24 weeks.

  Recruiting at 4 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 7 other locations · NCT07103746

• Microbes and allergic conditions in Mali

  This study will try to see if differences in microbes on and in the body and in the local environment are linked to asthma, eczema, or other allergic conditions in people in Bamako, Mali.

  Recruiting at 2 sites National Institute of Allergy and Infectious Diseases (NIAID) · Bamako and 1 other locations · NCT07051902

• Glecaprevir/pibrentasvir started during pregnancy for women with hepatitis C, with or without HIV

  This trial will test whether taking glecaprevir/pibrentasvir during pregnancy is safe and how the drug is processed in pregnant women who have hepatitis C, including those who also have HIV, and will follow their infants for 10 weeks after birth.

  Recruiting at 8 sites Phase 1/2 National Institute of Allergy and Infectious Diseases (NIAID) · Los Angeles, California and 9 other locations · NCT07040319

• Tezepelumab with Peanut OIT for Peanut Allergy

  This study tests whether adding tezepelumab to peanut oral immunotherapy can help people with peanut allergy build lasting tolerance.

  Recruiting at 6 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Little Rock, Arkansas and 9 other locations · NCT07015996

• Single intragraft injection of C1 esterase inhibitor to improve deceased-donor kidney transplant outcomes

  This trial will test whether injecting Berinert into deceased-donor kidneys before transplant helps adults on dialysis who are receiving high-risk deceased-donor kidney transplants have better kidney function over the first year.

  Recruiting at 4 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Los Angeles, California and 3 other locations · NCT06919003

• Treating antibody-mediated kidney transplant rejection with carfilzomib and belatacept

  We will test whether adding carfilzomib and belatacept to steroids and standard immunosuppression can safely reduce antibody-mediated injury in kidney transplant recipients with donor-specific antibodies.

  Recruiting at 9 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 10 other locations · NCT06918990

• Everolimus plus epoetin alfa to try to induce tolerance after liver transplant

  This phase 1b test will switch stable adult liver transplant patients from tacrolimus to everolimus, give five doses of epoetin alfa, and then slowly withdraw everolimus to see if they can safely stop maintenance immunosuppression.

  Recruiting at 3 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 2 other locations · NCT06832189

• Evaluating a new HIV vaccine regimen in healthy adults

  This study is testing a new HIV vaccine to see if it is safe and can help healthy adults build a strong immune response against the virus.

  Recruiting at 2 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 5 other locations · NCT06796686

• Characterizing immune responses to zoonotic virus exposure in Cambodia

  This study is testing how healthy adults in Cambodia respond to viruses from animals to better understand their immune reactions.

  Recruiting at 5 sites National Institute of Allergy and Infectious Diseases (NIAID) · Battambang and 4 other locations · NCT06680843

• Hiltonol‑adjuvanted CD40.HIVRI.Env (VRIPRO) vaccine in adults who completed HVTN 706

  This will test whether three doses of a vaccine candidate (CD40.HIVRI.Env with Hiltonol) are safe and boost immune responses in healthy adults who previously took part in HVTN 706.

  Recruiting at 4 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 8 other locations · NCT06665646

• Safety and dosing of two long‑lasting HIV antibodies in newborns

  This will try giving one or two long‑lasting HIV antibodies soon after birth to infants born to people with HIV to check safety and how long the antibodies stay in the baby's blood.

  Recruiting at 6 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Los Angeles, California and 18 other locations · NCT06517693

• Investigating a new treatment for atopic dermatitis using a specific bacteria

  This study is testing a new gel made with a specific bacteria to see if it helps teenagers and adults with atopic dermatitis who have a certain skin bacteria.

  Recruiting at 7 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Diego, California and 7 other locations · NCT06504160

• Using belatacept for heart transplant patients

  This study is testing if a new medication called belatacept can safely help heart transplant patients avoid rejection and complications compared to the usual treatment.

  Recruiting at 6 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Los Angeles, California and 7 other locations · NCT06478017

• Using Belumosudil to prevent lung transplant complications

  This study is testing if a new drug called Belumosudil can help prevent lung transplant complications in high-risk patients who have signs of rejection or inflammation.

  Recruiting at 12 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Los Angeles, California and 11 other locations · NCT06476132

• Registry to assess pregnancy outcomes in Mali

  This study is collecting information about pregnancy and baby health in Mali to help test new treatments for preventing malaria during pregnancy.

  Recruiting National Institute of Allergy and Infectious Diseases (NIAID) · Kalifabougou, Koulikoro · NCT06468319

• Minimizing immunosuppression in liver transplant patients using everolimus

  This study is testing if liver transplant patients can safely lower or stop taking tacrolimus by switching to everolimus to help protect their kidney function.

  Recruiting at 10 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Phoenix, Arizona and 11 other locations · NCT06280950

• Longitudinal study of asthma in urban children and adolescents

  This study is following urban kids and teens with and without asthma for a year to see how asthma affects their symptoms and daily life.

  Recruiting at 8 sites National Institute of Allergy and Infectious Diseases (NIAID) · Aurora, Colorado and 7 other locations · NCT06136091

• CMV vaccine for liver transplant candidates

  This study is testing a new vaccine for people waiting for a liver transplant to see if it can help prevent a virus called CMV and reduce the need for antiviral treatment after the transplant.

  Recruiting at 16 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 17 other locations · NCT06075745

• CAR-T cell therapy to help highly sensitized patients receive kidney transplants

  This study is testing if CAR T cell therapy can help highly sensitized patients who have been waiting for a kidney transplant by reducing their antibodies and making it easier for them to receive a transplant.

  Recruiting at 3 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Boston, Massachusetts and 2 other locations · NCT06056102

• Improving kidney transplant outcomes in children

  This study is testing a new combination of medications to see if it can help kids and teens who have had a kidney transplant do better and avoid organ rejection compared to the usual treatment.

  Recruiting at 19 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 20 other locations · NCT06055608

• Using Tocilizumab to improve outcomes in lung transplant patients

  This study is testing if adding Tocilizumab to the usual treatment can help lung transplant patients have better health outcomes compared to those who get a placebo.

  Recruiting at 13 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Phoenix, Arizona and 20 other locations · NCT06033196

• Comparing high and standard dose influenza vaccines in pediatric organ transplant recipients

  This study is testing whether a higher dose of the flu vaccine works better and is safe for kids aged 3 to 17 who have recently received an organ transplant.

  Recruiting at 11 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Stanford, California and 10 other locations · NCT05947071

• Using biomarkers to guide kidney transplant treatment

  This study is testing if a new way to measure genetic differences can help improve treatment and outcomes for adults getting their first kidney transplant.

  Recruiting at 13 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 14 other locations · NCT05917522

• Combination broadly neutralizing HIV antibodies given with ART during acute infection to try to induce remission

  This trial will try giving two HIV-specific broadly neutralizing antibodies along with starting ART to ART-naïve adults with acute HIV infection to see if it delays viral rebound and reduces the viral reservoir.

  Recruiting at 11 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 11 other locations · NCT05719441

• Using daratumumab to treat Primary Antiphospholipid Syndrome

  This study is testing if daratumumab can safely help people with Primary Antiphospholipid Syndrome feel better.

  Recruiting at 7 sites Phase 1/2 National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 7 other locations · NCT05671757

• Evaluating DON for treating pediatric cerebral malaria

  This study is testing if a new treatment called DON is safe and can help children aged 12 months to 14 years with cerebral malaria by improving their blood flow and brain health.

  Recruiting Phase 1/2 National Institute of Allergy and Infectious Diseases (NIAID) · Blantyre and 1 other locations · NCT05478720

• Six-month high-dose rifampicin and isoniazid with linezolid and pyrazinamide versus standard nine-month therapy for adult and adolescent tuberculous meningitis

  This study tests whether a six-month, high-dose antibiotic regimen (rifampicin, isoniazid, linezolid, and pyrazinamide) works better than the WHO nine-month treatment for adults and adolescents with tuberculous meningitis.

  Recruiting at 9 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Porto Alegre and 17 other locations · NCT05383742

• Registry for asthma characterization and recruitment

  This study is creating a database of information about childhood asthma in urban areas by enrolling around 1,500 participants of all ages to help with future research.

  Recruiting at 5 sites National Institute of Allergy and Infectious Diseases (NIAID) · Aurora, Colorado and 6 other locations · NCT05272241

• VIB4920 treatment for active lupus nephritis

  This study is testing if a new treatment called VIB4920, given with other medications, can help people with active lupus nephritis feel better and improve their kidney function.

  Recruiting at 15 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · La Jolla, California and 16 other locations · NCT05201469

• Comparing stem cell transplant to best available therapy for treatment-resistant multiple sclerosis

  This study is testing if a stem cell transplant can help people with treatment-resistant multiple sclerosis feel better compared to the best available therapies.

  Recruiting at 19 sites Phase 3 National Institute of Allergy and Infectious Diseases (NIAID) · Palo Alto, California and 22 other locations · NCT04047628

• Combining belimumab and rituximab for treating primary membranous nephropathy

  This study is testing if combining two medications, belimumab and rituximab, can help adults with primary membranous nephropathy feel better and achieve remission more effectively than using rituximab alone.

  Recruiting at 20 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 19 other locations · NCT03949855

• Vaginal microbiome exposure for newborns delivered by C-section

  This study is testing if exposing newborns delivered by C-section to their mother’s vaginal bacteria can improve their health and development over the first three years of life.

  Recruiting Phase 1/2 National Institute of Allergy and Infectious Diseases (NIAID) · Falls Church, Virginia · NCT03298334

• Long-term effects of immunomodulatory treatments in Type 1 Diabetes

  This study looks at people with Type 1 Diabetes who have tried certain treatments to see how long they can still make insulin and how their immune system changes over time.

  Recruiting at 8 sites National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 11 other locations · NCT02734277

• Early intensive treatment for infants with HIV to achieve remission

  This study is testing whether starting strong HIV treatment right after birth can help infants with HIV reach undetectable levels of the virus.

  Recruiting at 25 sites Phase 1/2 National Institute of Allergy and Infectious Diseases (NIAID) · La Jolla, California and 46 other locations · NCT02140255

Quick answers

How many clinical trials run by National Institute of Allergy and Infectious Diseases (NIAID) are recruiting right now?

50, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 22 countries. The most sites are in United States (44 trials), Zimbabwe (6 trials), Peru (5 trials), Brazil (4 trials), Kenya (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 19, Phase 1: 15, Phase 1/2: 6, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →